Size: | Price | Quantity | |
---|---|---|---|
5 mg | $60.00 | ||
25 mg | $200.00 |
Tafamidis (594839-88-0) is a potent and selective transthyretin (TTR) kinetic stabilizer. It binds selectively and with negative cooperativity to the two normally unoccupied thyroxine binding sites of the TTR tetramer (Kd = ~2 and ~200 nM)1. Stabilizes wild-type and mutant TTR under varying conditions in vitro (EC50=2.7-3.2 μM).1 Clinically useful for the treatment of familial amyloid polyneuropathy2,3 and TTR-related cardiomyopathy4.
References/Citations:
1) Bulawa et al. (2012), Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits amyloid cascade; Proc. Natl. Acad. Sci. USA, 109 9629
2) Scott (2014), Tafamidis: a review of its use in familial amyloid polyneuropathy; Drugs, 74 1371
3) Zhao et al. (2019), Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systemic Review and Meta-analysis; J. Clin. Neurol., 15 108
4) Lorenzini and Elliott (2019), Tafamidis for the treatment of transthyretin amyloidosis; Future Cardiol., 15 53
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Tafamidis (594839-88-0) is a potent and selective transthyretin (TTR) kinetic stabilizer. It binds selectively and with negative cooperativity to the two normally unoccupied thyroxine binding sites of the TTR tetramer (Kd = ~2 and ~200 nM)1. Stabilizes wild-type and mutant TTR under varying conditions in vitro (EC50=2.7-3.2 μM).1 Clinically useful for the treatment of familial amyloid polyneuropathy2,3 and TTR-related cardiomyopathy4.
References/Citations:
1) Bulawa et al. (2012), Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits amyloid cascade; Proc. Natl. Acad. Sci. USA, 109 9629
2) Scott (2014), Tafamidis: a review of its use in familial amyloid polyneuropathy; Drugs, 74 1371
3) Zhao et al. (2019), Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systemic Review and Meta-analysis; J. Clin. Neurol., 15 108
4) Lorenzini and Elliott (2019), Tafamidis for the treatment of transthyretin amyloidosis; Future Cardiol., 15 53
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.